Eslam A. Elghonaimy

Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways

Sherif Ibrahim, Ramy Gadalla, Eslam A. Elghonaimy et al. · Molecular Cancer · 2017 · 277 citations · Full text

Medicine, Cancer Biology, Oncology +17

Cytokines secreted by macrophages isolated from tumor microenvironment of inflammatory breast cancer patients possess chemotactic properties

Mona Mostafa Mohamed, Eslam A. Elghonaimy, Mohamed A. Nouh et al. · The International Journal of Biochemistry & Cell Biology · 2013 · 98 citations · Full text

Life Sciences, Immunology, Oncology +12

Human Cytomegalovirus Infection Enhances NF-κB/p65 Signaling in Inflammatory Breast Cancer Patients

Mohamed El‐Shinawi, Hossam Taha Mohamed, Eslam A. Elghonaimy et al. · PLoS ONE · 2013 · 69 citations · Full text

Medicine, Immunology, Oncology +12

Hormonal-receptor positive breast cancer: IL-6 augments invasion and lymph node metastasis via stimulating cathepsin B expression

Sherif Ibrahim, Eslam A. Elghonaimy, Hebatallah Hassan et al. · Journal of Advanced Research · 2016 · 42 citations · Full text

Medicine, Cancer Biology, Breast Oncology +12

The heparan sulfate proteoglycan syndecan‐1 regulates colon cancer stem cell function via a focal adhesion kinase—Wnt signaling axis

Sampath Kumar Katakam, Valeria Tria, W.S. Sim et al. · FEBS Journal · 2020 · 34 citations · Full text

Medicine, Cell Biology, Oncology +17